{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Treatment Satisfaction Questionnaire for Medication (TSQM) scores', 'Work Productivity and Activity Impairment Questionnaire (WPAI) scores', '7.1.6.', 'Part 2 Primary Enppoints', 'Number and proportion of subjects with a TEAE', 'Number and proportion of subjects who discontinue due to a TEAE', 'Number and proportion of subjects who experience a TESAE', 'Number and proportion of subjects who experience a Grade 3 or 4 TEAE', 'Number and proportion of subjects who experience a treatment-emergent Grade 3 or', '4 laboratory abnormality', 'The proportion of subjects with a treatment-emergent, treatment-related AE', 'consistent with a drug rash', '7.1.7.', 'Part 2 Secondary Enppoints', 'Number and rate of angioedema events', 'Durability of response (angioedema event rate trend over time)', 'Number and proportion of days with angioedema symptoms', 'Use of medications to treat angioedema events', 'Discontinuations due to lack of efficacy', 'Durability in AE-QoL questionnaire scores', 'Durability in EQ-5D-5L scores', 'Durability in TSQM scores', 'Durability in WPAI scores', '7.1.8.', 'Part 3 Primary Endpoints', 'Number and proportion of subjects with a TEAE', 'Number and proportion of subjects who discontinue due to a TEAE', 'Number and proportion of subjects who experience a TESAE', 'Number and proportion of subjects who experience a Grade 3 or 4 TEAE', 'Number and proportion of subjects who experience a treatment-emergent Grade 3 or', '4 laboratory abnormality', 'Proportion of subjects with a treatment-emergent, treatment-related AE consistent', 'with a drug rash', '7.1.9.', 'Part 3 Secondary Enppoints', 'Number and rate of angioedema events', 'Durability of response (angioedema event rate trend over time)', '41']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Number and proportion of days with angioedema symptoms', 'Use of medications to treat angioedema events', 'Durability in AE-QoL questionnaire scores', 'Durability in EQ-5D-5L scores', 'Durability in TSQM scores', 'Durability in WPAI scores', '8.', 'SELECTION AND WITHDRAWAL OF SUBJECTS', '8.1.', 'Number of Subjects', 'Approximately 24 subjects are planned to be enrolled in the study.', '8.2.', 'Subject Selection', '8.2.1.', 'Inclusion Criteria', 'Subjects must meet all of the following inclusion criteria to be eligible for participation in this', 'study:', '1.', 'Males and non-pregnant, non-lactating females > 12 years of age.', '2. Able to provide written, informed consent. Subjects who are aged 12 to 17 years at', 'screening must be able to read, understand, and be willing to sign an assent form in', 'addition to a caregiver providing informed consent.', '3.', 'A clinical diagnosis of HAE Type 1 or 2, defined as having a C1-INH functional level', '< 50% and a complement 4 (C4) level below the lower limit of the normal (LLN)', 'reference range, as assessed during the screening period.', 'In the absence of a low C4 value drawn during the intercritical period (ie, subject is not', 'having an angioedema event), one of the following is acceptable to confirm the diagnosis', 'of HAE: 1) a SERPING-1 gene mutation known or likely to be associated with HAE', 'Type 1 or 2 assessed during the screening period; 2) a confirmed family history of', 'C1-INH deficiency; 3) a C4 redrawn and retested during an angioedema event in the', 'screening period with the results below the LLN reference range.', 'For a C1-INH that is between 50% and the LLN (74%), a SERPING-1 gene mutation', 'known or likely to be associated with HAE Type 1 or 2 is acceptable to confirm the', 'diagnosis of HAE.', 'SERPING-1 gene analysis results indicating a \"possibly pathogenic\" mutation will be', 'considered on a case-by-case basis by the medical monitor and may require additional', 'testing for eligibility.', '4. Access to and ability to use an acute treatment for angioedema events approved by the', 'Japan Ministry of Health, Labor, and Welfare (plasma-derived C1-INH or icatibant).', '42']\n\n###\n\n", "completion": "END"}